|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heymann D and Rédini F: Targeted therapies
for bone sarcomas. Bonekey Rep. 2:3782013. View Article : Google Scholar :
|
|
3
|
Yarber JL and Agulnik M: Targeted
therapies in bone sarcomas: Current approach and future directions.
Expert Opin Investig Drugs. 20:973–979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosa A and Brivanlou AH: MicroRNAs in
early vertebrate development. Cell Cycle. 8:3513–3520. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang H, Yu W-W, Wang L-L and Peng Y:
miR-130a acts as a potential diagnostic biomarker and promotes
gastric cancer migration, invasion and proliferation by targeting
RUNX3. Oncol Rep. 34:1153–1161. 2015.PubMed/NCBI
|
|
9
|
Lee SH, Jung YD, Choi YS and Lee YM:
Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases
cell proliferation and tumor angiogenesis in gastric cancer cells.
Oncotarget. 6:33269–33278. 2015.PubMed/NCBI
|
|
10
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013.PubMed/NCBI
|
|
11
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li B, Huang P, Qiu J, Liao Y, Hong J and
Yuan Y: MicroRNA-130a is down-regulated in hepatocellular carcinoma
and associates with poor prognosis. Med Oncol. 31:2302014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang J, Han S, Huang W, Chen T, Liu Y, Pan
S and Li S: A meta-analysis of microRNA expression in liver cancer.
PLoS One. 9:e1145332014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujita Y, Kojima T, Kawakami K, Mizutani
K, Kato T, Deguchi T and Ito M: miR-130a activates apoptotic
signaling through activation of caspase-8 in taxane-resistant
prostate cancer cells. Prostate. 75:1568–1578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boll K, Reiche K, Kasack K, Mörbt N,
Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn
F, et al: MiR-130a, miR-203 and miR-205 jointly repress key
oncogenic pathways and are downregulated in prostate carcinoma.
Oncogene. 32:277–285. 2013. View Article : Google Scholar
|
|
16
|
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long
G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion
and migration in human breast cancer by targeting the RAB5A. Int J
Clin Exp Pathol. 8:384–393. 2015.PubMed/NCBI
|
|
17
|
Stückrath I, Rack B, Janni W, Jäger B,
Pantel K and Schwarzenbach H: Aberrant plasma levels of circulating
miR-16, miR-107, miR-130a and miR-146a are associated with lymph
node metastasis and receptor status of breast cancer patients.
Oncotarget. 6:13387–13401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei SC, Fattet L and Yang J: The forces
behind EMT and tumor metastasis. Cell Cycle. 14:2387–2388. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heerboth S, Housman G, Leary M, Longacre
M, Byler S, Lapinska K, Willbanks A and Sarkar S: EMT and tumor
metastasis. Clin Transl Med. 4:62015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu M, Jin H, Xu CX, Sun B, Song ZG, Bi WZ
and Wang Y: miR-382 inhibits osteosarcoma metastasis and relapse by
targeting Y box-binding protein 1. Mol Ther. 23:89–98. 2015.
View Article : Google Scholar :
|
|
22
|
Benjamin RS: Osteosarcoma: Better
treatment through better trial design. Lancet Oncol. 16:12–13.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Parsons R and Simpson L: PTEN and cancer.
Tumor Suppressor Genes. El-Deiry WS: Springer; New York: pp.
147–166. 2003, View Article : Google Scholar
|
|
26
|
Nielsen-Preiss SM, Silva SR and Gillette
JM: Role of PTEN and Akt in the regulation of growth and apoptosis
in human osteoblastic cells. J Cell Biochem. 90:964–975. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kun C, Zongsheng Y and Yong H: Effects of
PTEN gene transfection on apoptosis of human osteosarcom cell line
MG-63 [J]. Acta Universitatis Medicinalis Anhui. 5:0122007.
|
|
28
|
Hu Y, Xu S, Jin W, Yi Q and Wei W: Effect
of the PTEN gene on adhesion, invasion and metastasis of
osteosarcoma cells. Oncol Rep. 32:1741–1747. 2014.PubMed/NCBI
|
|
29
|
Tian K, Di R and Wang L: MicroRNA-23a
enhances migration and invasion through PTEN in osteosarcoma.
Cancer Gene Ther. 22:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kawano M, Tanaka K, Itonaga I, Ikeda S,
Iwasaki T and Tsumura H: microRNA-93 promotes cell proliferation
via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res.
34:762015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shang Y, Wang L-Q, Guo Q-Y and Shi T-L:
MicroRNA-196a overexpression promotes cell proliferation and
inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway. Int J Clin
Exp Pathol. 8:2461–2472. 2015.PubMed/NCBI
|
|
32
|
Liu CJ, Yu KL, Liu GL and Tian DH: MiR-214
promotes osteosarcoma tumor growth and metastasis by decreasing the
expression of PTEN. Mol Med Rep. 12:6261–6266. 2015.PubMed/NCBI
|
